The North American-AIDS Cohort Collaboration on Research and Design (NA-ACCORD) has represented Region 1 of the leDEA initiative since 2006. The 22 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV/AIDS cohorts within the US and Canada. Over 200 sites in the US and Canada contribute data collected from 150,000 HIV-infected participants. We have established a strong collaborative infrastructure that capitalizes on the talents and expertise of multi-disciplinary group of investigators that span basic science, clinical research, epidemiology, data informatics and biostatistics. We have been highly productive in addressing our previous Aims and expanding our scientific focus to several areas of contemporary importance in HIV in North America, and our collaboration is well- positioned to answer the key questions in practice today. We have three broadly-defined aims for the next funding cycle:
Aim 1 : Assess and characterize the clinical course of HIV infection in North America, with a focus on aging, major non-AIDS comorbidities and life-expectancy.
Aim 2 : Characterize the HIV Care Continuum in North America from engagement in HIV care through viral suppression, and extend the Continuum to include long-term retention, utilization of ART to clinical outcomes and life-expectancy.
Aim 3 : Assess the impact of new direct-acting antivirals (DAAs) on the progression and outcomes of HIV and hepatitis C (HCV) disease in HIV-HCV co-infected persons. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to provide definitive answers to these issues of contemporary relevance in the U.S. and Canada. In addition, we will expand our collaboration with other leDEA regions to both inform future experience in resource-limited regions as the treatment of the epidemics mature, and to identify and understand differences in treatment, outcomes and prognostic factors that might inform future research and clinical care globally.

Public Health Relevance

The NA-ACCORD is the most wide-ranging collaboration of HIV cohorts that exists within North America. Its large sample size, the comprehensiveness and quality of its data, combined with the expert use of state-of-the-art statistical methods will allo us to provide answers to what we believe are the most pressing questions of contemporary importance for the care and outcomes of HIV-infected individuals in the U.S. and Canada. These questions will focus the clinical course and outcomes of treated HIV infection, the HIV Care Continuum and the treatment of HIV-hepatitis C coinfection.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Zimand, Lori B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903
Eyawo, Oghenowede; McGinnis, Kathleen A; Justice, Amy C et al. (2018) Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr 77:135-143
Oh, Eric J; Shepherd, Bryan E; Lumley, Thomas et al. (2018) Considerations for analysis of time-to-event outcomes measured with error: Bias and correction with SIMEX. Stat Med 37:1276-1289
Lesko, Catherine R; Jacobson, Lisa P; Althoff, Keri N et al. (2018) Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. Int J Epidemiol 47:654-668
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Lee, Jennifer S; Cole, Stephen R; Achenbach, Chad J et al. (2018) Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS One 13:e0197665

Showing the most recent 10 out of 160 publications